TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...

With both new and revised measures, the document’s authors aim to provide clinicians usable advice in a digestible format.

Cath labs need to be redesigned so that operators aren’t at risk for future injury, even if it requires some hospital ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

A trend toward higher mortality in women with PPM who received a self-expanding valves deserves more scrutiny, though.